Simulations Plus Reports Record Second Quarter FY2020 Revenue
Quarterly Revenues Up 22%; Board of Directors Announces Quarterly Dividend of $0.06 Per Share
Live Stream Learning with Simulations Plus Day Two
Bringing you scientific talks & poster presentations you missed from the 59th Annual SOT/Tox Expo and American Society for Clinical Pharmacology & Therapeutics conference by Simulations Plus… virtually.
Stochastic Assessment of Adaptive Volunteer Infection Study (aVIS) Designs in Malaria – A Case Study with Artefenomel
Traditional Malaria Volunteer infection studies use three consecutive single dose level cohorts (n=8).
Development and Evaluation of a Simulation Platform for Malaria Volunteer Infection Study (VIS) Designs
Traditional malaria volunteer infection studies have three consecutive single-dose cohorts.
Early assessment of PK properties with the ADMET Predictor® HTPK Simulation module, a high-throughput mechanistic PBPK approach
This webinar introduces how the ADMET Predictor® HTPK Simulation module can effectively be used to provide early PK assessment in discovery programs.
Live Stream Learning with Simulations Plus: Day One
Bringing you scientific talks & poster presentations you missed from the 59th Annual SOT/Tox Expo and American Society for Clinical Pharmacology & Therapeutics conference by Simulations Plus… virtually.
Simulations Plus Partners with Large Pharmaceutical Company to Enhance High-Throughput PBPK Capabilities in ADMET Predictor®
Updated Functionality Seamlessly Integrates Mechanistic Modeling in Drug Discovery
Modeling DILI Drug-Drug Interactions with DILIsym
DILIsym Services, Inc. offers comprehensive program services:
Clinical DILI and State-of-the-Art Solutions
Translating in vitro safety data into quantitative risk assessment in specific patient populations remains a challenge.
Simulations Plus Sets Date for 2nd Quarter 2020 Earnings Release and Conference Call
Conference Call to be on Thursday, April 9, 2020, at 4:15 PM ET
Feature of the week #84: VPC for time-to-event data
VPC of survival data is a crucial diagnostic plot in the modeling of time-to-event data
Simulations Plus Acquires Lixoft, Expanding Modeling Software Offerings and Broadening Presence in Europe
Accretive acquisition adds Monolix Suite, a population PKPD modeling solution for pharmacometricians
Translational Modeling Strategies for Orally Administered Drug Products: Academic, Industrial and Regulatory Perspectives
During non-clinical and clinical development of a new molecular entity (NME), modeling and simulation (M&S) are routinely used to predict...
Simulations Plus Sets Date for 2nd Quarter 2020 Earnings Release and Conference Call
Conference Call to be on Thursday, April 9, 2020, at 4:15 PM ET
A next generation risk assessment case study for coumarin in cosmetic products
Next Generation Risk Assessment (NGRA) is defined as an exposure-led, hypothesis-driven risk assessment approach that...
Physiologically-based pharmacokinetic models for children: Starting to reach maturation?
Developmental changes in children can affect the disposition and clinical effects of a drug, indicating that scaling an...
Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer
Alflutinib (AST2818) is a third-generation epidermal growth factor receptor (EGFR) inhibitor that inhibits both EGFR-sensitive mutations and T790M mutations.
Liver toxicity of anthraquinones: A combined in vitro cytotoxicity and in silico reverse dosimetry evaluation
Anthraquinones are found in a variety of consumer products such as dietary supplements, traditional Chinese medicines, and drugs.